Use of vasopressor in pediatric shock management across the world: A scoping reviews of practices, outcomes and gaps in 2026
This 2026 scoping review synthesizes global evidence from 2020–2025 to highlight a shift toward earlier vasopressor initiation and peripheral administration in pediatric shock management, while identifying critical gaps in first-line agent consensus, safety protocols, and standardized guidelines that necessitate further randomized trials and education.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine your body is a bustling city. The roads are your blood vessels, and the delivery trucks are your red blood cells, carrying oxygen and fuel to every neighborhood. Sometimes, a disaster strikes—a flood, a fire, or a massive traffic jam. In the medical world, this disaster is called shock. It's not just a feeling of being tired; it's a critical emergency where the city's roads can't deliver enough supplies to keep the buildings (your organs) from shutting down. To fix this, doctors often use special tools called vasopressors. Think of these as traffic controllers that squeeze the roads tighter to push the delivery trucks faster and raise the pressure in the system, ensuring the city doesn't go dark. For a long time, doctors had a strict rulebook: "First, pour in a massive amount of water (fluids) to fill the pipes, and only then if the city is still struggling, turn on the traffic controllers." But what if that rulebook is outdated? What if turning on the controllers sooner, or even using them in a different way, could save the city faster? This is the big question scientists are asking when they look at how we treat sick children in shock.
A team of researchers from Debre Berhan University decided to play detective. They didn't run new experiments themselves; instead, they gathered and sorted through 12 different studies published between 2020 and 2025 from all over the world, from the United States to India, and from Brazil to France. They wanted to see what the real-world evidence said about using these "traffic controllers" (vasopressors) in pediatric shock. Their goal was to map out what doctors are actually doing, what results they are getting, and where the map still has blank spots.
Here is what their investigation revealed. First, they found that the old rule of "wait until you've poured in 40 to 60 mL of fluid per kilogram of body weight" might be too slow. Several studies suggested that starting the vasopressors earlier—perhaps after just the first 20 mL/kg of fluid—acts like a faster response team. This approach seems to keep the city from getting flooded with too much water (fluid overload), helps kids recover faster, and gets them out of the Pediatric Intensive Care Unit (PICU) sooner. It's like realizing that sometimes, you need to open the floodgates of the traffic controllers before the roads are completely submerged, rather than waiting for the water to rise to a dangerous level first.
Second, the researchers discovered that the "traffic controllers" don't always need to be plugged into the main power grid (a central vein deep in the chest). For years, doctors were terrified of using them in the smaller, outer roads (peripheral veins in the arms or hands) because they feared the chemicals would leak out and damage the tissue. However, new evidence suggests that with careful watching, these drugs can be safely given through peripheral lines, especially during emergencies or while moving a patient. It's like realizing you can use a portable generator to keep the lights on while you wait for the main power line to be fixed, rather than waiting in the dark.
However, the investigation also uncovered some tricky parts of the map. There is still no clear agreement on which "traffic controller" is the absolute best one to start with. While some doctors prefer norepinephrine, others still use epinephrine or dopamine, and the studies show mixed results. One drug, vasopressin, showed promise for tough cases but came with a warning label: it caused a significant drop in salt levels (hyponatremia) in many children, especially newborns, sometimes leading to dangerous neurological risks. This suggests that if we use this specific tool, we need a very strict safety checklist.
The paper also highlighted that the biggest gap isn't just about the drugs; it's about the people using them. Many healthcare providers struggle to recognize shock early or follow the guidelines consistently, leading to delays. The researchers noted that relying on just one number, like the "cardiac index" (a measure of how hard the heart is pumping), isn't enough. Just because the heart is pumping hard doesn't mean the roads are clear; other factors like how full the pipes are or how stiff they are matter too.
In the end, this review suggests that the way we treat pediatric shock is evolving. The evidence points toward starting vasopressors earlier, being brave enough to use peripheral lines when necessary, and moving away from rigid, one-size-fits-all rules. But the authors are careful to note that we don't have all the answers yet. There is a desperate need for more large, high-quality studies to prove exactly which drug is best, when to start it, and how to dose it safely. Until then, the medical community is learning to be more flexible, treating each child's "city" as unique, and working to fill in the blank spots on the map to save more lives.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.